[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Prenosis, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,37],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100644886",false,"NCT07675265","Observational, Non-interventional Biomarker and Endotyping Study","Observational Biomarker Study for the Evaluation of Response and Validation of Endotypes in Acute Respiratory Distress Syndrome","OBSERVE-ARDS","Inclusion Criteria:\n\n* Age ≥18 years\n* ARDS Diagnosis (New Global Definition of ARDS)\n* Timing: Acute onset within 7 days\n* Radiology: Bilateral pulmonary opacities\n* Hypoxia:\n\nNon-intubated ARDS: PaO2:FIO2\\\u003C300mmHg or SpO2:FIO2\\\u003C315 (if SpO2\\\u003C97%) on HFNO with flow of \\>30 L\u002Fmin or NIV\u002FCPAP with at least 5 cm H2O end-expiratory pressure; or Intubated ARDS: PaO2:FIO2\\\u003C300 mm Hg or SpO2:FIO2\\\u003C315 (if SpO2\\\u003C97%)\n\n* ICU admission\n* Enrolled within 72 hours of meeting inclusion criteria\n\nExclusion Criteria:\n\n• Primary cardiogenic pulmonary edema","ALL","18 Years",{"count":19,"type":20},1200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to establish a centralized ARDS biorepository of longitudinal biospecimens and harmonized clinical data, develop unsupervised, therapy-agnostic endotyping algorithms, and develop unsupervised, therapy-specific treatment-prediction algorithms over a 24 month period.",[24],"ARDS (Acute Respiratory Distress Syndrome)","NOT_YET_RECRUITING","2026-06-23",{"date":28,"type":29},"2026-06-30","ACTUAL",{"date":31,"type":20},"2026-07",{"date":33,"type":20},"2029-03",{"name":35,"class":36},"Prenosis, Inc.","INDUSTRY",{"id":38,"slug":4,"hasResults":10,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":43,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":45,"conditions":46,"keywords":48,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":4},"100634731","NCT07543497","Performance and Impact of the Sepsis ImmunoScore","Clinical Utility and Performance of the Sepsis ImmunoScore: A Prospective Cohort Device Study","Inclusion Criteria:\n\n* Adult (age 18 years or older) patients presenting to hospitals and emergency departments of medical institutions across the United States.\n* Adult (age 18 years or older) patients suspected of sepsis.\n\nExclusion Criteria:\n\n* none",{"count":44,"type":20},5000,"The goal of this prospective cohort device study is to assess clinical usage and impact, diagnostic performance, and prognostic performance of the Sepsis ImmunoScore.",[47],"Sepsis",[49],"sepsis","2026-04-15",{"date":52,"type":29},"2026-04-22",{"date":54,"type":20},"2026-04",{"date":56,"type":20},"2027-12",{"name":35,"class":36},""]